TAR-210 results show 90 percent recurrence-free survival and 90 percent complete response in patients with high-risk and intermediate-risk non-muscle-invasive bladder cancer, respectively
May 05, 2024 14:39 ET
|
Janssen Cilag International NV
Updated results reinforce the potential of TAR-210 to transform treatment of non-muscle-invasive bladder cancer with fibroblast growth factor receptor (FGFR) alterations1 BEERSE, BELGIUM, May 05,...
AKRO INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Akero Therapeutics, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Case
May 04, 2024 13:04 ET
|
Robbins Geller Rudman & Dowd LLP
SAN DIEGO, May 04, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that it has filed a class action lawsuit seeking to represent purchasers of Akero Therapeutics, Inc....
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Exscientia, and Akero and Encourages Investors to Contact the Firm
May 03, 2024 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, May 03, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of...
Compass Pathways to announce first quarter financial results on May 8, 2024
May 03, 2024 16:58 ET
|
Compass Pathways
LONDON, May 03, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health,...
Vision Sensing Acquisition Corp. Announces Payment of Fee to Extend Period to Consummate Initial Business Combination to June 3, 2024
May 03, 2024 16:30 ET
|
Vision Sensing Acquisition Corp.
Vision Sensing Acquisition Corp. Announces Payment of Fee to Extend Period to Consummate Initial Business Combination to June 3, 2024
Phase 2 data for ERLEADA® ▼(apalutamide) plus androgen deprivation therapy following radical prostatectomy in patients with high-risk localised prostate cancer shows 100 percent biochemical free recurrence rate more than two years post-surgery
May 03, 2024 12:39 ET
|
Janssen Cilag International NV
Study highlights opportunity for treatment intensification in this population since approximately 50 percent of patients with high-risk localised prostate cancer (HRLPC) experience disease recurrence...
TAR-200 monotherapy shows greater than 80 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer
May 03, 2024 11:53 ET
|
Janssen Cilag International NV
New data from Phase 2b SunRISe-1 study show rapid achievement of complete response (CR) with 98 percent achieving a CR within 12 weeks1 TAR-200 provides durable CRs in patients with Bacillus...
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
May 03, 2024 11:23 ET
|
CG Oncology Inc.
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Contact Levi & Korsinsky by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation (AVXL)
May 03, 2024 09:57 ET
|
Levi & Korsinsky, LLP
NEW YORK, May 03, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Anavex Life Sciences Corporation ("Anavex Life Sciences" or the "Company") (NASDAQ: AVXL) of a class action...
PDS Biotechnology Announces Details of Virtual KOL Event
May 03, 2024 08:00 ET
|
PDS Biotechnology Corporation
PRINCETON, N.J., May 03, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the...